GLOBAL ACCELERATOR FOR PAEDIATRIC FORMULATIONS (GAP-f)

Webinar: Report back from the Paediatric Antituberculosis Drug Optimization 1 Meeting (PADO-TB 1)
27 February 2019

Building on the success of a similar approach in HIV (Paediatric Antiretroviral Drug Optimization), the inaugural Paediatric Antituberculosis Drug Optimization 1 Meeting (PADO-TB 1) took place in February 2019. The PADO-TB 1 meeting objectives were to: (1) discuss the PADO for TB platform and its mode of operation, (2) develop a list of short/medium- and long-term priorities for paediatric TB drug optimization, and (3) agree on a way forward to accelerate development and uptake of the priority medicine formulations. The development of a consensus priority list of paediatric antituberculosis drugs and formulations will complement work in the TB field, including efforts to accelerate paediatric drug and formulation development from the Global Accelerator for Paediatric Formulations (GAP-f), which aims to accelerate paediatric drug development and uptake across disease areas, including HIV, TB and viral hepatitis.

Webinar: Outcomes of the Paediatric ARV Drug Optimization 4 (PADO 4) and Paediatric Hepatitis C Drug Optimization meetings
19 December 2018

The WHO-led Paediatric ARV Drug Optimization 4 (PADO 4) and Paediatric Hepatitis C Drug Optimization meetings took place from 10-12 December 2018. These groups provide evidence-based priority lists with clear and consistent message to guide industry and interested stakeholders on the most needed formulations to be developed. The lists help reduce the number of unnecessary formulations being developed, and continue to be a critical tool to focus efforts and resources. The webinar covered the main outcomes of these prioritization exercises with regards to paediatric HIV and HCV drug optimization.

Webinar series: Toolkit for Research and Development of Paediatric Antiretroviral Drugs and Formulations
October 2018 – January 2019

The Toolkit for Research and Development of Paediatric Antiretroviral Drugs and Formulations is an initiative of the WHO and its Paediatric ARV Working Group (PAWG), in collaboration with Unitaid, IMPAACT and PENTA-ID. It identifies the challenges and solutions for promoting and accelerating timely and high-quality research and development of antiretroviral drug formulations suitable for infants, children, adolescents, and pregnant and breastfeeding women. This webinar series, convened by the GAP-f, provided an overview of each of the modules of the toolkit. It included module authors as presenters, with other stakeholders presenting their perspective on the importance of this work.

AIDS 2018 satellite on “Accelerating the development and uptake of the most needed drug formulations for children”
23 July 2018 | Amsterdam, the Netherlands

Limited treatment options and sub-optimal formulations contribute to poor adherence and outcomes for children living with HIV and other diseases that affect the lives of children living in resource-limited settings. The Global Accelerator for Paediatric Formulations (GAP-f) aims to promote a faster, more efficient and more focused approach to paediatric formulation development. This session presented key principles for acceleration – and how these are brought together by the GAP-f – for different areas of the continuum, with a focus on: (1) prioritization and clinical research of priority formulations, (2) development and regulatory approval of paediatric drug formulations, and (3) uptake and procurement of optimal formulations for children. A panel discussed (1) the value and opportunities for an integrated approach to paediatric medicines and (2) the business case and innovative funding. The session ended with an overview of what to watch in paediatric drug optimization.

ILF Webinar: Report back on PADO 3 review 
5 February 2018

With the availability of new evidence, and progress in the development of new drugs (including paediatric formulations), the Paediatric ARV Drug Optimization (PADO) group recently reviewed its list of priority paediatric ARV formulations. In collaboration with the WHO and CHAI, the ILF hosted a webinar to report back on the PADO 3 review.